| Intra-Cellular Therapies, Inc. (ITI) is a biotechnology company developing novel therapeutics for the treatment of depression, schizophrenia, Alzheimer's and Parkinson's disease and other disorders of the Central Nervous System. Using IntraPath, its broad technology platform, ITI has identified nerve-signaling proteins, validated their roles in vivo and is currently using these proteins as targets for small molecule drugs. Commercializing the Nobel-prize winning research of Dr. Paul Greengard, ITI is uniquely positioned to develop novel therapies for neuropsychiatric and neurodegenerative disorders. With its broad expertise in the molecular basis of neurotransmitter and drug action, ITI is validating drug candidates for its internal drug discovery programs and for its pharmaceutical partners. Founded by Drs. Greengard, Sharon Mates and Allen Fienberg, ITI began operations in May 2002 and is headquartered in the Audubon Biomedical Science & Technology Park in New York City.
|
